Abstract
Type 2 diabetes mellitus (T2DM) is a global public health problem often associated with obesity. Bariatric surgery is effective for treating serious obesity, and techniques involving intestinal bypass have metabolic benefits, such as complete and early remission of T2DM. We present a literature review of the possible mechanisms of early normalization of glycemic homeostasis after bariatric surgery, including intestinal gluconeogenesis, increased antidiabetogenic signals from L cells located in the distal small intestine, and impaired secretion of diabetogenic signals in the upper part of the small intestine. Adding to these potential mechanisms, unknown factors that regulate insulin sensitivity may be involved and altered by bariatric surgery. This review discusses the various hypotheses about the mechanisms of glycemic control after bariatric surgery involving intestinal bypass. Further research is essential to better understand these mechanisms and to identify potential new mechanisms that might help in developing less invasive and safer alternatives for the treatment of T2DM and reveal novel pharmaceutical targets for glycemic control.
Similar content being viewed by others
References
World Health Organization. Facts sheet on diabetes, obesity and overweight. Geneva: World Health Organization; 2006.
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
Bottino R, Trucco M. Multifaceted therapeutic approaches for a multigenic disease. Diabetes. 2005;54:79–86.
Wilson JB, Pories WJ. Durable remission of diabetes after bariatric surgery: what is the underlying pathway? Insulin. 2010;5:46–55.
Masharami U, Karam JH, et al. Hôrmonios pancreáticos e diabetes melito. In: Greenspan FS, Gardner DG, editors. Endocrinologia Básica e Clínica. New York: McGraw-Hill; 2006. p. 541–55.
Sartorelli DS, Franco LJ. Trends in diabetes mellitus in Brazil: the role of the nutritional transition. Cad Saúde Pública. 2003;19:29–36.
Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Toronto: Canadian Diabetes Association; 2008. p. 77.
Shafrir E. Development and consequences of insulin resistance: lessons from animals with hyperinsulinaemia. Diabetes Metab. 1996;22:122–31.
Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171–6.
Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009;35:518–23.
Rubino F, Marescaux J. Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Annals of Surg. 2004;239:1–11.
Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89:2608–15.
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Annals of Surg. 2003;238:467–84.
Pories WJ, Swanson MS, McDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Annals of Surg. 1995;222:339–50.
Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025–31.
Mari A, Manco M, Guidone C, et al. Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetol. 2006;49:2136–43.
Pories WJ, Caro JF, Flickinger EG, et al. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Annals of Surg. 1987;206:316–23.
Salinari S, Bertuzzi A, Asnaghi S, et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care. 2009;32:375–80.
Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Annals of Surg. 2004;240:236–42.
Briatore L, Salani B, Andraghetti G, et al. Restoration of acute insulin response in T2DM subjects 1 month after biliopancreatic diversion. Obes. 2008;16:77–81.
American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32:13–61.
Scheen AJ, De Flines J, De Roover A, et al. Bariatric surgery in patients with type 2 diabetes: benefits, risks, indications and perspectives. Diabetes Metab. 2009;35:537–43.
Crookes PF. Surgical treatment of morbid obesity. Annu Rev Med. 2006;57:243–64.
Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab. 2008;93:89–96.
Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 2009;19:1605–11.
Mason EE, Doherty C, Cullen JJ, et al. Vertical gastroplasty: evolution of vertical banded gastroplasty. World J Surg. 1998;22:919–24.
Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393–411.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.
Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care. 2008;3:290–6.
Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005;28:2406–11.
Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20:1245–50.
Kashyap SR, Gatmaitan P, Brethauer S, et al. Bariatric surgery for type 2 diabetes: weighing the impact for obese patients. Cleve Clin J Med. 2010;77:468–76.
Polonsky KS, Gumbiner B, Ostrega D, et al. Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes. 1994;43:871–7.
Gumbiner B, Van Cauter E, Beltz WF, et al. Abnormalities of insulin pulsatility and glucose oscillations during meals in obese noninsulin-dependent diabetic patients: effects of weight reduction. J Clin Endocrinol Metab. 1196;81:2061–8.
Sugerman HJ, Wolfe LG, Sica DA. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Annals of Surg. 2003;237:751–8.
Dixon JB. Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes. World J Surg. 2009;33:2014–21.
Parikh M, Duncombe J, Fielding GA. Laparoscopic adjustable gastric banding for patients with body mass index of ≤35 kg/m2. Surg Obes Relat Dis. 2006;2:518–22.
Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.
Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond). 2009;33:33–40.
Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev. 1198;78:1087–108.
Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117:24–32.
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–65.
Mithieux G. The new functions of the gut in the control of glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2005;8:445–9.
Delaere F, Magnan C, Mithieux G. Hypothalamic integration of portal glucose signals and control of food intake and insulin sensitivity. Diabetes Metab. 2010;36:257–62.
Cui XL, Sotenopoulos P, Tolias P, et al. Fructose-responsive genes in the small intestine of neonatal rats. Physiol Genomics. 2004;18:206–17.
Kirchner S, Seixas P, Kaushik S, et al. Effect of low protein intake on extra-hepatic, gluconeogenic enzyme expression and peripheral, glucose phosphorylation in rainbow trout. Comp Biochem Physiol B Biochem Nol Biol. 2005;140:333–40.
Yanez AJ, Nualart F, Droppelmann C, et al. Broad expression of fructose-1,6-bisphosphatase and phosphoenolpyruvate carboxykinase provide evidence for gluconeogenesis in human issues other than liver and kidney. J Cell Physiol. 2003;197:189–97.
Chatelain F, Pegorier JP, Minassian C, et al. Development and regulation of glucose-6 phosphatase gene expression in liver, intestine and kidney; in vivo and in vitro studies in cultured fetal hepatocytes. Diabetes. 1998;47:882–9.
She P, Burgess SC, Shiota M, et al. Mechanisms by which liver-specific PEPCK knockout mice preserve euglycemia during starvation. Diabetes. 2003;52:1649–54.
Battezzati A, Caumo A, Martino F, et al. Non hepatic glucose production in humans. Am J Physiol Endocrinol Metab. 2004;286:E124–35.
Troy S, Soty M, Ribeiro L, et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab. 2008;8:201–11.
Mithieux G. A novel function of intestinal gluconeogenesis: central signaling in glucose and energy homeostasis. Nutrition. 2009;25:881–4.
Bikman BT, Zheng D, Pories WJ, et al. Mechanisms for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab. 2008;93:4656–63.
Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs. Diab Vasc Dis Res. 2007;4:150–2.
Kashyap SR, Daud S, Kelly KR, et al. Acute effect of gastric bypass versus gastric restrictive surgery on B-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond). 2010;34:462–71.
Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15:474–81.
Strader AD, Vahl TP, Jandacek RJ, et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab. 2005;288:E447–53.
Patriti A, Facchiano E, Annetti C, et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg. 2005;15:1258–64.
Patriti A, Aisa MC, Annetti C, et al. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto–Kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surg. 2007;142:74–85.
Karra E, Yousseif A, Batterham RL. Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. Trends Endocrinol Metab. 2010;21:337–44.
Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Annals of Surg. 2006;244:741–9.
Rodriguez-Grunert L, Galvao Neto MP, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal–jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4:55–9.
Tarnoff M, Sorli C, Rodriguez L, et al. Interim report of a prospective, randomized sham controlled trial investigating a completely endoscopic duodenal–jejunal bypass sleeve for the treatment of type 2 diabetes. Diabetes. 2008;57:A32.
Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling. Diabetol. 2009;52:2270–6.
Aronoff SL, Berkowitz K, Shreiner B, et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr. 2004;17:183–90.
Holst JJ. Extra-pancreatic glucagons. Dig. 1978;17:168–90.
Holst JJ, Pedersen JH, Baldissera F, et al. Circulating glucagon after total pancreatectomy in man. Diabetol. 1983;25:396–9.
Novak U, Wilks A, Buell G, et al. Identical messenger-Rna for preproglucagon in pancreas and gut. Eur J Biochem. 1987;164:553–8.
Mojsov S, Heinrich G, Wilson IB, et al. Preproglucagon gene-expression in pancreas and intestine diversifies at the level of posttranslational processing. J Biol Chem. 1986;261:11880–9.
Orskov C, Holst JJ, Knuhtsen S, et al. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinol. 1986;119:1467–75.
Orskov C, Holst JJ, Poulsen SS, et al. Pancreatic and intestinal processing of proglucagon in man. Diabetol. 1987;30:874–81.
Orskov C, Andreasen J, Holst JJ. All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab. 1992;74:379–84.
Orskov C, Bersani M, Johnsen AH, et al. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem. 1989;264:12826–9.
Thim L, Moody AJ. The primary structure of porcine glicentin (proglucagon). Regul Pept. 1981;2:139–50.
Vilsboll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2 diabetes mellitus. Dan Med Bull. 2004;51:364–70.
Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717–23.
Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301–7.
Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353:249–54.
Chevallier JM. Gastric banding using adjustable silastic ring in 2010. Technique, indications, results, and management. J Visceral Surg. 2010;147S:e21–9.
Baltasar A, Serra C, Perez N, et al. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. Obes Surg. 2005;15:1124–8.
Kremen A, Linner JH, Nelson CH. An experimental evaluation of the nutritional importance of proximal and distal small intestine. Ann Surg. 1954;140:439–48.
Griffen WO, Bivins BA, Bell RM. The decline and fall of jejunoileal bypass. Surg Gynecol Obstet. 1983;157:301–8.
Thomas S, Schauer P. Bariatric surgery and the gut hormone response. Nutr Clin Pract. 2010;25:175–82.
Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surg. 1996;119:261–8.
Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg. 1998;8:267–82.
Cummings DE, Foster-Schubert KE, Overduin J. Ghrelin and energy balance: focus on current controversies. Curr Drug Targets. 2005;6:153–69.
Kuntz E, Pinget M, Damge P. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. JOP. 2004;5:464–75.
Ahren B, Holst JJ, Efendic S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab. 2000;85:1043–8.
Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetol. 2003;46:798–801.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterol. 2007;132:2131–57.
Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation and apoptosis. Mol Endocrinol. 2003;17:161–71.
Ohneda A, Ohneda K, Nagasaki T, et al. Insulinotropic action of human glicentin in dogs. Metabolism. 1195;44:47–51.
Sinclair EM, Drucker DJ. Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiol (Bethesda). 2005;20:357–65.
Maida A, Lovshin JA, Baggio LL, et al. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances β-cell function but does not inhibit gastric emptying in mice. Endocrinol. 2008;149:5670–8.
Laferrere B, Swerdlow N, Bawa B, et al. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95:4072–6.
Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab. 2005;90:359–65.
Chan JL, Mun EC, Stoyneva V, et al. Peptide YY levels are elevated after gastric bypass surgery. Obes (Silver Spring). 2006;14:194–8.
van den Hoek AM, Heijboer AC, Corssmit EP, et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes. 2004;53:1949–52.
Acknowledgments
The author is grateful to the members of her team and her many collaborators, among them the designer André Galleoti Kobal, who produced the figures.
Conflict of Interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sala, P.C., Torrinhas, R.S., Heymsfield, S.B. et al. Type 2 Diabetes Mellitus: A Possible Surgically Reversible Intestinal Dysfunction. OBES SURG 22, 167–176 (2012). https://doi.org/10.1007/s11695-011-0563-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-011-0563-2